Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGastroenterologic OncologyradiotherapyDiseaseAnal CarcinomaSubgroupPD-L1+unfitICD10C21.-C21.0C21.1C21.2C21.8MeSHAnus NeoplasmsSequenceChemotherapyChemo-substanceCapecitabineCarboplatinCisplatinDocetaxelFluorouracilFolinic acidMitomycinNivolumabPaclitaxelPembrolizumabChemo-substanceCapecitabineCarboplatinCisplatinDocetaxelFluorouracilFolinic acidMitomycinNivolumabPaclitaxelPembrolizumabChemo-substanceCapecitabineCarboplatinCisplatinDocetaxelFluorouracilFolinic acidMitomycinNivolumabPaclitaxelPembrolizumabChemo-substanceCapecitabineCarboplatinCisplatinDocetaxelFluorouracilFolinic acidMitomycinNivolumabPaclitaxelPembrolizumabNo. Substances123 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideNo. Substances1267Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseTherapy intentioncurativepalliativeRisksAnemia Hb below 8g/dlArthalgiaAstheniaCardiotoxicityColitisConstipationDehydrationDiarrheaEmetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHand-Foot SyndromeHyperglycemiaHyperkalemiaHyperthyroidismHypothyroidismInfectionsMucositisNeuropathyNeutropeniaOtotoxicityPneumonitisRadiation DermatitisRashRenal FailureThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorAjani JAKim SMondaca SMorris VKOtt PARao SThind GDiseaseAnalkarzinom, Plattenepithel-, metastasiert oder nichtresezierbares Rezidiv, ECOG 0-1 lokal fortgeschrittenes, nicht operables oder metastasiertes Analkarzinom, PD-L1+, Zweitlinientherapie, ECOG 0-1lokal fortgeschrittenes, nicht operables oder metastasiertes Analkarzinom, Zweitlinientherapie, ECOG 0-1Metastasiertes oder fortgeschrittenes Anal-Ca, nichtresezierbar, ECOG 0-1Plattenepithel- , Basalzell- oder kloakogenes Anal-Ca, T2-T4, jedes N, M0Plattenepithel- oder kloakogenes Anal-Ca, Stadium I-III, ECOG 0-2wiederkehrendes oder metastasiertes, nicht resezierbares Analkarzinom, ECOG 0-1OriginCenter for Immuno-Oncology, Dana-Farber Cancer Institute, BostonDepart. of Gastroint. Med. Oncology, Anderson Cancer Center, Texas, USA. Intergroup RTOG 98-11 StudieDepartment of Oncology, University Hospital of Besancon, Besançon, FranceMemorial Sloan Kettering Cancer CenterRoyal Marsden Hospital, London, United Kingdom, INTERAACT trialThe British Columbia Cancer AgencyThe University of Texas, MD Anderson Cancer Center, Houston, USA, NCI9673Protocols in Revision 8 protocols foundProtocols under revision.Capecitabine 825 / Mitomycin 12 / Radiation, Anal Carcinoma (PID481 V1.1)Cisplatin 40 / Folinic Acid 400 / Fluorouracil 1000, Anal Carcinoma (PID1978 V1.1)Fluorouracil 1000 / Cisplatin 100, Anal Carcinoma (PID482 V1.1)Fluorouracil 1000 / Mitomycin 10 / Radiation, Anal Carcinoma (PID480 V1.1)modified Docetaxel 40 / Cisplatin 40 / Fluorouracil 1200, Anal Carcinoma (PID628 V1.2)Nivolumab 240, Anal Carcinoma (PID1749 V1.0)Paclitaxel 80 / Carboplatin 5, Anal Carcinoma (PID1352 V1.3)Pembrolizumab 200, Anal Carcinoma (PID1750 V1.0)
